Jun 2026 (Q2 FY26) — Aug 3, 2026
Medifast Q2 FY26 — Strategic Shift to Metabolic Health with Trilivi Launch
Read the full callMedifast (MED) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Medifast earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 76.4 | −27.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.7 | −4.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -3.1 | −225.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$12.03 +1.26% · +$0.15
Performance −6.9% 1Y
1Y: $12.92 on 17 Oct 2025 → $12.03. High $13.15 (28 May 2026), low $9.45 (23 Jul 2026).
- Previous close
- $11.88
- 52-week range
- $9.45 – $13.15
- One year
- −5.42%
Overview
- Symbol
- MED
- Sector
- Consumer Discretionary
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Medifast earnings calls (MED)
Financials
What the filings say
Net profit, year on year: −225% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 140 | 119 | 116 | 106 | 89 | 75 | 76 | 76 |
| Operating profit | 2 | 1 | -1 | -1 | -4 | -8 | -3 | -4 |
| Operating margin | 1.5% | 0.6% | −1.1% | −1.0% | −4.6% | −10.4% | −4.3% | −5.7% |
| Other income | -1 | 1 | 2 | 4 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 1 | 1 | 3 | -3 | -6 | -2 | -3 |
| Tax rate | 28.4% | 37.2% | 246.8% | 13.7% | 14.9% | −183.9% | −9.3% | −3.6% |
| Net profit | 1 | 1 | -1 | 2 | -2 | -18 | -2 | -3 |
| EPS ($ per share) | 0.10 | — | -0.07 | 0.23 | -0.21 | — | -0.19 | -0.28 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 131 | 169 | 154 | 190 | 140 | 175 | 177 | 158 |
| Total liabilities | 60 | 90 | 119 | 196 | 161 | 108 | 74 | 49 |
| Fixed assets | 20 | 26 | 28 | 56 | 57 | 51 | 38 | 31 |
| Investments | 20 | 16 | 11 | 5 | 0 | 56 | 71 | 78 |
| Total assets | 169 | 195 | 276 | 398 | 316 | 310 | 284 | 248 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 61 | 84 | 145 | 95 | 195 | 148 | 24 | 7 |
| Cash from investing | -1 | -6 | -1 | -29 | -11 | -61 | -27 | -8 |
| Cash from financing | -53 | -82 | -57 | -125 | -200 | -80 | -2 | -1 |
| Net cash flow | 6 | -4 | 87 | -60 | -16 | 7 | -4 | -2 |
| Capital expenditure | -5 | -10 | -6 | -34 | -17 | -6 | -7 | -6 |
| Free cash flow | 56 | 74 | 139 | 60 | 178 | 141 | 17 | 1 |
Insider filings
34 filings between Mar 13, 2026 and Sep 29, 2026.
Open market
decisions to buy or sellPurchases
$1.67M
11 purchases by 3 insiders
Sales
$226.3K
2 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 9
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kiai Parsa | $1.42M | — | Aug 26, 2026 |
| Chard Daniel R | $178.7K | $226.3K | Sep 29, 2026 |
| SCHLACKMAN SCOTT | $63.0K | — | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Chard Daniel R Director | Sale 10b5-1 plan | 9,544 | $112.0K |
| Sep 28, 2026 | Chard Daniel R Director | Sale 10b5-1 plan | 9,545 | $114.3K |
| Aug 26, 2026 | Kiai Parsa Director | Purchase | 1,175 | $14.4K |
| Aug 26, 2026 | Kiai Parsa Director | Purchase | 41,975 | $514.7K |
| Aug 24, 2026 | Kiai Parsa Director | Purchase | 118 | $1.4K |
| Aug 24, 2026 | Kiai Parsa Director | Purchase | 4,211 | $50.5K |
| Aug 20, 2026 | Kiai Parsa Director | Purchase | 1,175 | $13.6K |
| Aug 20, 2026 | Kiai Parsa Director | Purchase | 41,975 | $487.1K |
| Aug 19, 2026 | Kiai Parsa Director | Purchase | 28,538 | $332.7K |
| Aug 19, 2026 | Kiai Parsa Director | Purchase | 799 | $9.3K |
| May 26, 2026 | Kiai Parsa Director | Award | 7,637 | $0 |
| May 26, 2026 | Geary Elizabeth A. Director | Award | 11,680 | $0 |
| May 26, 2026 | Rose Jeffrey Matthew Director | Award | 6,739 | $0 |
| May 26, 2026 | Rose Jeffrey Matthew Director | Award | 11,680 | $0 |
| May 26, 2026 | SCHLACKMAN SCOTT Director | Award | 11,680 | $0 |
| May 26, 2026 | Thomas Andrea B Director | Award | 11,680 | $0 |
| May 26, 2026 | Kiai Parsa Director | Award | 11,680 | $0 |
| May 11, 2026 | SCHLACKMAN SCOTT Director | Purchase | 2,500 | $31.3K |
| May 8, 2026 | SCHLACKMAN SCOTT Director | Purchase | 2,500 | $31.6K |
| Mar 25, 2026 | MacKenzie Jonathan Barrett VP, Finance & CAO | Tax withheld | 862 | $8.3K |
| Mar 25, 2026 | Chard Daniel R Chairman & CEO | Tax withheld | 20,095 | $192.7K |
| Mar 25, 2026 | Chard Daniel R Chairman & CEO | Award | 36,968 | $0 |
| Mar 25, 2026 | Maloney James P. Chief Financial Officer | Tax withheld | 3,224 | $30.9K |
| Mar 25, 2026 | Maloney James P. Chief Financial Officer | Award | 34,344 | $0 |
| Mar 25, 2026 | Maloney James P. Chief Financial Officer | Award | 1,014 | $0 |
| Mar 25, 2026 | MacKenzie Jonathan Barrett VP, Finance & CAO | Award | 10,830 | $0 |
| Mar 25, 2026 | Chard Daniel R Chairman & CEO | Award | 4,827 | $0 |
| Mar 20, 2026 | Chard Daniel R Chairman & CEO | Purchase | 17,678 | $178.7K |
| Mar 17, 2026 | MacKenzie Jonathan Barrett VP, Finance & CAO | Tax withheld | 70 | $704 |
| Mar 17, 2026 | Maloney James P. Chief Financial Officer | Tax withheld | 482 | $4.8K |
| Mar 17, 2026 | Chard Daniel R Chairman & CEO | Tax withheld | 2,638 | $26.5K |
| Mar 13, 2026 | Maloney James P. Chief Financial Officer | Tax withheld | 918 | $8.8K |
| Mar 13, 2026 | Chard Daniel R Chairman & CEO | Tax withheld | 7,075 | $68.1K |
| Mar 13, 2026 | MacKenzie Jonathan Barrett VP, Finance & CAO | Tax withheld | 198 | $1.9K |
| Jun 25, 2025 | Thomas Andrea B Director | Award | 11,168 | $0 |
| Jun 25, 2025 | SCHLACKMAN SCOTT Director | Award | 11,168 | $0 |
| Jun 25, 2025 | BROWN JEFFREY J Director | Award | 9,449 | $126.5K |
| Jun 25, 2025 | Geary Elizabeth A. Director | Award | 11,168 | $0 |
| Jun 25, 2025 | Hoer Michael A. Director | Award | 11,168 | $0 |
| Jun 25, 2025 | BROWN JEFFREY J Director | Award | 11,168 | $0 |
| Jun 13, 2025 | Chard Daniel R Chairman & CEO | Purchase | 381 | $5.0K |
| Mar 25, 2025 | Maloney James P. Chief Financial Officer | Award | 24,161 | $0 |
| Mar 25, 2025 | MacKenzie Jonathan Barrett VP, Finance & CAO | Award | 7,671 | $0 |
| Mar 25, 2025 | Chard Daniel R Chairman & CEO | Award | 124,953 | $0 |
| Mar 17, 2025 | Chard Daniel R Chairman & CEO | Tax withheld | 1,864 | $26.7K |
| Mar 17, 2025 | MacKenzie Jonathan Barrett VP, Finance & CAO | Tax withheld | 99 | $1.4K |
| Mar 17, 2025 | Maloney James P. Chief Financial Officer | Tax withheld | 438 | $6.3K |
| Mar 16, 2025 | MacKenzie Jonathan Barrett VP, Finance & CAO | Tax withheld | 60 | $836 |
| Mar 16, 2025 | Chard Daniel R Chairman & CEO | Tax withheld | 944 | $13.2K |
| Mar 16, 2025 | Maloney James P. Chief Financial Officer | Tax withheld | 123 | $1.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MEDIFAST INC
Free account. Everything above stays public.
Write why you follow MEDIFAST INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading